Including Patient Input In Patient-Reported Outcome Instrument Development: Examples From the MDASI-CML
Abstract 2573 The United States Food and Drug Administration (FDA) recognizes patient-reported outcomes (PROs) as acceptable measures of treatment benefit and risk in medical product clinical trials. The FDA requires that patient input be included in the development and testing of PRO instruments. W...
Saved in:
Published in | Blood Vol. 116; no. 21; p. 2573 |
---|---|
Main Authors | , , , , , |
Format | Journal Article |
Language | English |
Published |
Elsevier Inc
19.11.2010
|
Online Access | Get full text |
Cover
Loading…
Abstract | Abstract 2573
The United States Food and Drug Administration (FDA) recognizes patient-reported outcomes (PROs) as acceptable measures of treatment benefit and risk in medical product clinical trials. The FDA requires that patient input be included in the development and testing of PRO instruments. We have adopted a three-step process for the development of multi-symptom PROs that includes patient input in each step. This method is being used for the development of the M. D. Anderson Symptom Inventory (MDASI) for Philadelphia-chromosome-positive chronic myeloid leukemia (CML). The MDASI is a PRO measure of symptom burden, defined as the combined impact of all disease-related and therapy-related symptoms on one's ability to function as one did before the onset of disease or therapy, in patients with cancer. The core MDASI includes 13 symptom severity items and 6 interference items rated at their worst in the last 24 hours on a 0–10 scale, with 0 meaning no symptom or interference and 10 meaning as bad as can be imagined or complete interference.
The first step in the process was qualitative interviews with 35 patients with CML about their symptom experiences. Symptoms were extracted by descriptive exploratory analysis from interview transcripts. Step 2 was grading of the relevance of the symptoms (0 to 4 scale) from Step 1 by an expert panel that included professional care providers as well as patients with CML and their family caregivers. Symptoms that received a mean relevance rating of ≥ 3 were added to the 13 symptom items and 6 interference items of the core MDASI for validation in Step 3. One hundred and sixty patients with CML are completing the experimental MDASI-CML, which will undergo psychometric validation and item reduction. The first 30 patients in Step 3 completed a cognitive debriefing interview about their experience of completing the MDASI-CML.
Patient characteristics are in Table 1. No personal information was collected on the expert panel members.
Thirty-nine symptoms (13 core and 26 CML-specific) were extracted from the Step 1 qualitative interviews and rated by the expert panel. Four physicians, 5 nurses, 3 patients, and 3 family caregivers returned ratings. Six of the 26 CML-specific items had mean relevance ratings of ≥ 3. The experimental MDASI-CML includes the 13 core symptoms, 6 CML-specific symptoms, and 6 core interference items (Table 2).
Table 2MDASI-CML ItemsCORE SYMPTOM ITEMSCML-SPECIFIC SYMPTOM ITEMSINTERFERENCE ITEMSPainDiarrheaGeneral activitiesFatigueSwellingMoodNauseaRash or skin changesWork (including around the house)Disturbed sleepMuscle soreness or crampingRelations with othersDistressEasy bruising or bleedingWalkingShortness of breathMalaise (not feeling well)Enjoyment of lifeTrouble rememberingLack of appetiteDrowsiness (sleepiness)Dry mouthSadnessVomitingNumbness or tingling
During the cognitive debriefing, over 80% of patients reported that the MDASI-CML items were not at all difficult to complete or understand, were completely comfortable to answer, and were not repetitive, and that the 0–10 scoring system for rating severity of symptoms and interference with daily activities was very easy to use. Nine patients listed 12 additional symptoms that should be included, but each symptom was only mentioned by 1 patient and had already been eliminated because of low relevance ratings by the expert panel.
Inclusion of patient input at each step of PRO development ensures that the instrument measures what is important to patients and enhances content validity. It further ensures that the measure is easy to understand and complete. Psychometric validation of the MDASI-CML is proceeding.
No relevant conflicts of interest to declare. |
---|---|
AbstractList | Abstract 2573
The United States Food and Drug Administration (FDA) recognizes patient-reported outcomes (PROs) as acceptable measures of treatment benefit and risk in medical product clinical trials. The FDA requires that patient input be included in the development and testing of PRO instruments. We have adopted a three-step process for the development of multi-symptom PROs that includes patient input in each step. This method is being used for the development of the M. D. Anderson Symptom Inventory (MDASI) for Philadelphia-chromosome-positive chronic myeloid leukemia (CML). The MDASI is a PRO measure of symptom burden, defined as the combined impact of all disease-related and therapy-related symptoms on one's ability to function as one did before the onset of disease or therapy, in patients with cancer. The core MDASI includes 13 symptom severity items and 6 interference items rated at their worst in the last 24 hours on a 0–10 scale, with 0 meaning no symptom or interference and 10 meaning as bad as can be imagined or complete interference.
The first step in the process was qualitative interviews with 35 patients with CML about their symptom experiences. Symptoms were extracted by descriptive exploratory analysis from interview transcripts. Step 2 was grading of the relevance of the symptoms (0 to 4 scale) from Step 1 by an expert panel that included professional care providers as well as patients with CML and their family caregivers. Symptoms that received a mean relevance rating of ≥ 3 were added to the 13 symptom items and 6 interference items of the core MDASI for validation in Step 3. One hundred and sixty patients with CML are completing the experimental MDASI-CML, which will undergo psychometric validation and item reduction. The first 30 patients in Step 3 completed a cognitive debriefing interview about their experience of completing the MDASI-CML.
Patient characteristics are in Table 1. No personal information was collected on the expert panel members.
Thirty-nine symptoms (13 core and 26 CML-specific) were extracted from the Step 1 qualitative interviews and rated by the expert panel. Four physicians, 5 nurses, 3 patients, and 3 family caregivers returned ratings. Six of the 26 CML-specific items had mean relevance ratings of ≥ 3. The experimental MDASI-CML includes the 13 core symptoms, 6 CML-specific symptoms, and 6 core interference items (Table 2).
Table 2MDASI-CML ItemsCORE SYMPTOM ITEMSCML-SPECIFIC SYMPTOM ITEMSINTERFERENCE ITEMSPainDiarrheaGeneral activitiesFatigueSwellingMoodNauseaRash or skin changesWork (including around the house)Disturbed sleepMuscle soreness or crampingRelations with othersDistressEasy bruising or bleedingWalkingShortness of breathMalaise (not feeling well)Enjoyment of lifeTrouble rememberingLack of appetiteDrowsiness (sleepiness)Dry mouthSadnessVomitingNumbness or tingling
During the cognitive debriefing, over 80% of patients reported that the MDASI-CML items were not at all difficult to complete or understand, were completely comfortable to answer, and were not repetitive, and that the 0–10 scoring system for rating severity of symptoms and interference with daily activities was very easy to use. Nine patients listed 12 additional symptoms that should be included, but each symptom was only mentioned by 1 patient and had already been eliminated because of low relevance ratings by the expert panel.
Inclusion of patient input at each step of PRO development ensures that the instrument measures what is important to patients and enhances content validity. It further ensures that the measure is easy to understand and complete. Psychometric validation of the MDASI-CML is proceeding.
No relevant conflicts of interest to declare. Abstract Abstract 2573 Introduction: The United States Food and Drug Administration (FDA) recognizes patient-reported outcomes (PROs) as acceptable measures of treatment benefit and risk in medical product clinical trials. The FDA requires that patient input be included in the development and testing of PRO instruments. We have adopted a three-step process for the development of multi-symptom PROs that includes patient input in each step. This method is being used for the development of the M. D. Anderson Symptom Inventory (MDASI) for Philadelphia-chromosome-positive chronic myeloid leukemia (CML). The MDASI is a PRO measure of symptom burden, defined as the combined impact of all disease-related and therapy-related symptoms on one's ability to function as one did before the onset of disease or therapy, in patients with cancer. The core MDASI includes 13 symptom severity items and 6 interference items rated at their worst in the last 24 hours on a 0–10 scale, with 0 meaning no symptom or interference and 10 meaning as bad as can be imagined or complete interference. Patients and Methods: The first step in the process was qualitative interviews with 35 patients with CML about their symptom experiences. Symptoms were extracted by descriptive exploratory analysis from interview transcripts. Step 2 was grading of the relevance of the symptoms (0 to 4 scale) from Step 1 by an expert panel that included professional care providers as well as patients with CML and their family caregivers. Symptoms that received a mean relevance rating of ≥ 3 were added to the 13 symptom items and 6 interference items of the core MDASI for validation in Step 3. One hundred and sixty patients with CML are completing the experimental MDASI-CML, which will undergo psychometric validation and item reduction. The first 30 patients in Step 3 completed a cognitive debriefing interview about their experience of completing the MDASI-CML. Results: Patient characteristics are in Table 1. No personal information was collected on the expert panel members. Thirty-nine symptoms (13 core and 26 CML-specific) were extracted from the Step 1 qualitative interviews and rated by the expert panel. Four physicians, 5 nurses, 3 patients, and 3 family caregivers returned ratings. Six of the 26 CML-specific items had mean relevance ratings of ≥ 3. The experimental MDASI-CML includes the 13 core symptoms, 6 CML-specific symptoms, and 6 core interference items (Table 2). During the cognitive debriefing, over 80% of patients reported that the MDASI-CML items were not at all difficult to complete or understand, were completely comfortable to answer, and were not repetitive, and that the 0–10 scoring system for rating severity of symptoms and interference with daily activities was very easy to use. Nine patients listed 12 additional symptoms that should be included, but each symptom was only mentioned by 1 patient and had already been eliminated because of low relevance ratings by the expert panel. Conclusions: Inclusion of patient input at each step of PRO development ensures that the instrument measures what is important to patients and enhances content validity. It further ensures that the measure is easy to understand and complete. Psychometric validation of the MDASI-CML is proceeding. Disclosure: No relevant conflicts of interest to declare. |
Author | Williams, Loretta A Garcia-Gonzalez, Araceli Cortes, Jorge E. Cleeland, Charles S Williams, Janet L Ault, Patricia S |
Author_xml | – sequence: 1 givenname: Loretta A surname: Williams fullname: Williams, Loretta A organization: Symptom Research, The University of Texas MD Anderson Cancer Center, Houston, TX, USA – sequence: 2 givenname: Jorge E. surname: Cortes fullname: Cortes, Jorge E. organization: Leukemia, The University of Texas MD Anderson Cancer Center, Houston, TX, USA – sequence: 3 givenname: Patricia S surname: Ault fullname: Ault, Patricia S organization: Symptom Research, The University of Texas MD Anderson Cancer Center, Houston, TX, USA – sequence: 4 givenname: Araceli surname: Garcia-Gonzalez fullname: Garcia-Gonzalez, Araceli organization: Symptom Research, The University of Texas MD Anderson Cancer Center, Houston, TX, USA – sequence: 5 givenname: Janet L surname: Williams fullname: Williams, Janet L organization: Symptom Research, The University of Texas MD Anderson Cancer Center, Houston, TX, USA – sequence: 6 givenname: Charles S surname: Cleeland fullname: Cleeland, Charles S organization: Symptom Research, The University of Texas MD Anderson Cancer Center, Houston, TX, USA |
BookMark | eNqFkMtOwzAQRS1UJNrCN5AfSPDEebKr-oBIrYqgYms59rgEJXHkJBX8PUkLazZ3RvO4mjkzMqlNjYTcA_UAEv8hL41R3jtA5Png-WHMznJFphD6iUupTydkSimN3CCN4YbM2vaTUgiYH07JMatl2auiPjovoiuw7pysbvpR_wruKzbGdqicfd9JU-HQazvbV-PwCk9YmmbMH531l6iaEltnY03ldB_o7FaLt8xd7ra35FqLssW73zgnh836sHx2t_unbLnYuhIiytxQ-0rlEDFMkSY0l1SD0jpGlYBgGOc6EHkMmOaBYFKIgGGYaABFtY5UyuYkvthKa9rWouaNLSphvzlQPuLiZ1x8xMV94COpswybi8smDtedCrS8lcP3ElVhUXZcmeJfjx_3M3kJ |
CitedBy_id | crossref_primary_10_1038_s41375_023_01888_y crossref_primary_10_1016_j_jpainsymman_2013_02_007 crossref_primary_10_2147_PPA_S394332 |
ContentType | Journal Article |
Copyright | 2010 American Society of Hematology |
Copyright_xml | – notice: 2010 American Society of Hematology |
DBID | 6I. AAFTH AAYXX CITATION |
DOI | 10.1182/blood.V116.21.2573.2573 |
DatabaseName | ScienceDirect Open Access Titles Elsevier:ScienceDirect:Open Access CrossRef |
DatabaseTitle | CrossRef |
DatabaseTitleList | CrossRef |
DeliveryMethod | fulltext_linktorsrc |
Discipline | Medicine Chemistry Biology Anatomy & Physiology |
EISSN | 1528-0020 |
EndPage | 2573 |
ExternalDocumentID | 10_1182_blood_V116_21_2573_2573 S0006497119446405 |
GroupedDBID | --- -~X .55 1CY 23N 2WC 34G 39C 4.4 53G 5GY 5RE 5VS 6I. 6J9 9M8 AAEDW AAFTH AAXUO ABOCM ABVKL ACGFO ADBBV AENEX AFFNX AFOSN AHPSJ ALMA_UNASSIGNED_HOLDINGS BAWUL BTFSW CS3 DIK DU5 E3Z EBS EJD EX3 F5P FDB FRP GS5 GX1 IH2 K-O KQ8 L7B LSO MJL N4W N9A OK1 P2P R.V RHF RHI ROL SJN THE TR2 TWZ W2D W8F WH7 WOQ WOW X7M YHG YKV ZA5 0R~ 0SF AALRI AAYXX ADVLN AITUG AKRWK AMRAJ CITATION H13 |
ID | FETCH-LOGICAL-c1603-5f2ddb163e9e080bc0f1dff7ed81a3e7bf4ab71e9b4a3caa43e58f11d0ff6d93 |
IEDL.DBID | ABVKL |
ISSN | 0006-4971 |
IngestDate | Fri Aug 23 00:27:36 EDT 2024 Fri Feb 23 02:43:42 EST 2024 |
IsDoiOpenAccess | true |
IsOpenAccess | true |
IsPeerReviewed | true |
IsScholarly | true |
Issue | 21 |
Language | English |
License | This article is made available under the Elsevier license. |
LinkModel | DirectLink |
MergedId | FETCHMERGED-LOGICAL-c1603-5f2ddb163e9e080bc0f1dff7ed81a3e7bf4ab71e9b4a3caa43e58f11d0ff6d93 |
OpenAccessLink | https://www.sciencedirect.com/science/article/pii/S0006497119446405 |
PageCount | 1 |
ParticipantIDs | crossref_primary_10_1182_blood_V116_21_2573_2573 elsevier_sciencedirect_doi_10_1182_blood_V116_21_2573_2573 |
PublicationCentury | 2000 |
PublicationDate | 2010-11-19 |
PublicationDateYYYYMMDD | 2010-11-19 |
PublicationDate_xml | – month: 11 year: 2010 text: 2010-11-19 day: 19 |
PublicationDecade | 2010 |
PublicationTitle | Blood |
PublicationYear | 2010 |
Publisher | Elsevier Inc |
Publisher_xml | – name: Elsevier Inc |
SSID | ssj0014325 |
Score | 2.0273798 |
Snippet | Abstract 2573
The United States Food and Drug Administration (FDA) recognizes patient-reported outcomes (PROs) as acceptable measures of treatment benefit and... Abstract Abstract 2573 Introduction: The United States Food and Drug Administration (FDA) recognizes patient-reported outcomes (PROs) as acceptable measures of... |
SourceID | crossref elsevier |
SourceType | Aggregation Database Publisher |
StartPage | 2573 |
Title | Including Patient Input In Patient-Reported Outcome Instrument Development: Examples From the MDASI-CML |
URI | https://dx.doi.org/10.1182/blood.V116.21.2573.2573 |
Volume | 116 |
hasFullText | 1 |
inHoldings | 1 |
isFullTextHit | |
isPrint | |
link | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwpV3dS8MwED_GxI8X0U1xfpEH8S1b06Zp69s2NzZ1KviBbyVpEhm4OtSB_vcmaSsKgg--hBI4KHfh7nfJ7-4AjgiTklIRYt_3Iky5jjD3KMeJokwLkUgS2HrnySUb3dGzh_ChBv2qFsbSKkvfX_h0563LnU6pzc58OrU1viacJhExaThl1PYxXfLtM1Mdlrq9-_OLr8cEGvjFIAOTPFuBkuZlkHXHscPb94Swtm-yxTAK3PJ7kPoWeIYbsF4iRtQtfmoTaipvQLObm2x59oGOkeNwusvxBiz3qq_VfjXJrQErk_IBvQmPxh88LWy8QtdFR1U0zucLu1YbuMDkSqKrxZtRi0Jj12XWXiOibxyjEzR457a38CsavjzPkEGSaHLavRnj_uRiC26Hg9v-CJezFnBmB03jUPtSCgPOVKIMiBSZp4nUOlIyJjxQkdCUi4ioRFAeZJzTQIWxJkR6WjOZBNtQz59ztQPI5Lk81lnCA1tzy1QswpgxTRmJPSYy1QKv0m06LzpqpC4Tif3UmSO15kh9klpLuKUFJ5UN0h-HIzV-_y_h3f8I78GaowtY3l-yD3WjbXVgUMibOCxP2aHB4ePzTy2V2e0 |
link.rule.ids | 315,786,790,27600,27955,27956,45696 |
linkProvider | Elsevier |
linkToHtml | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwpV1RSxwxEB5EafVF2rNFa1vzUPoWb7ObzW58O68ed3prC72KbyHZJEWo62E90H_fSXZXLBT64EtYAoFlZpj5JvlmBuATE9ZybnKapklBufYF1QnXVDouvDHSsizUO1fnYvqDn17ml2sw7mthAq2y8_2tT4_eutsZdtIcLq-uQo0vhlNZMEzDueChj-kGogGJZr4xOr44mz8-JvAsbQcZYPIcDnQ0L0TWw8gOP7xgTBymmC3mRRaXfwepJ4Fn8gq2O8RIRu1PvYY11wxgZ9Rgtnz9QD6TyOGMl-MDeHHcf22O-0luA3hZdQ_oO_AT_cGvVYhX5FvbUZXMmuUqrP0GbTG5s-Tr6g7F4sgsdpkN14jkCcfoiJzc69Bb-DeZ3N5cE0SSpPoy-j6j42r-BhaTk8V4SrtZC7QOg6Zp7lNrDYIzJx2CSFMnnlnvC2dLpjNXGM-1KZiThuus1ppnLi89YzbxXliZvYX15qZxu0Awz9Wlr6XOQs2tcKXJSyE8F6xMhKndHiS9bNWy7aihYiZSpiqqQwV1qJSpoIm47MFRrwP1l3Eo9Pv_O_zuOYcPYHO6qOZqPjs_24etSB0IHED5HtZR8u4DIpI787GzuD-GGdvt |
openUrl | ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=Including+Patient+Input+In+Patient-Reported+Outcome+Instrument+Development%3A+Examples+From+the+MDASI-CML&rft.jtitle=Blood&rft.au=Williams%2C+Loretta+A&rft.au=Cortes%2C+Jorge+E.&rft.au=Ault%2C+Patricia+S&rft.au=Garcia-Gonzalez%2C+Araceli&rft.date=2010-11-19&rft.pub=Elsevier+Inc&rft.issn=0006-4971&rft.eissn=1528-0020&rft.volume=116&rft.issue=21&rft.spage=2573&rft.epage=2573&rft_id=info:doi/10.1182%2Fblood.V116.21.2573.2573&rft.externalDocID=S0006497119446405 |
thumbnail_l | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=0006-4971&client=summon |
thumbnail_m | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=0006-4971&client=summon |
thumbnail_s | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=0006-4971&client=summon |